atrophic facial acne scars atrophic scar
Conditions
Interventions
The participant will be administered with hyaluronic acid solution by the EnerJet2.0 system (pneumatic needle-free injection technology) into individual facial scars by assigning one side of the face
therapy
Sponsors
Yuki Yamamoto
Chikako Kaminaka
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Male or female 25-65 years old. Presence of more than 4 distensible facial moderate to severe atrophic acne scars.
Exclusion criteria
Exclusion criteria: Patient with having severe underlying disease, pregnancy or lactation, Porphyria, cardiac conduction disturbance, allergic conditioned, local anesthesia allergies and hyaluronic acid produced allergies previously, vascular or bleeding disorders, treated with anticoagulant therapy, autoimmune disease, treated with immunosuppressive therapy, keloid scar formation, hypertrophic scar formation, malignant skin tumor, pigment anomaly, inflammatory disease that a symptom may aggravate in irritation by a treatment, medical history of herpesvirus infection. Invasive aesthetic treatments or facial surgery within 6 months prior to the study enrollment. Physical or chemical aesthetic treatments within 3 month prior to the study enrollment. Clinically significant acne in the proposed treatment areas defined as more than 3 active inflammatory acne lesions in the treatment areas.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall judgment of therapeutic efficacy | — |
Secondary
| Measure | Time frame |
|---|---|
| time-to-treatment-failure, adverse events | — |
Contacts
Public ContactKaminaka Chikako
Wakayama Medical University Hospital
Outcome results
None listed